Abstract | OBJECTIVE: PATIENTS AND METHODS: A total of 20 elderlies, naïve to opioids and with persistent moderate-to-severe chronic pain from different etiologies received tapentadol PR with up-titrations as necessary. The response to treatment, defined as at least 30% reduction in pain intensity compared with baseline, was the primary endpoint. Secondary endpoints were pain intensity on the Numeric Rating Scale (NRS) both at rest and during loading and sleep quality. RESULTS:
Tapentadol PR was safe and effective in our population of elderlies with chronic pain from different etiologies: pain intensity compared with baseline, both at rest and during load, was statistically lower at each visit (p<0.01), whereas sleep quality improved significantly throughout the study (p<0.05). Only few minor side effects were reported, with an overall good safety profile and a very high tolerability and satisfaction for treatment. CONCLUSIONS:
Tapentadol PR, adequately titrated according to patients' response in naïve subjects, is safe and effective to control pain in the elderly.
|
Authors | C Aurilio |
Journal | European review for medical and pharmacological sciences
(Eur Rev Med Pharmacol Sci)
Vol. 23
Issue 4 Suppl
Pg. 40-44
(Nov 2019)
ISSN: 2284-0729 [Electronic] Italy |
PMID | 31755085
(Publication Type: Journal Article, Observational Study)
|
Chemical References |
- Analgesics, Opioid
- Delayed-Action Preparations
- Tapentadol
|
Topics |
- Aged
- Analgesics, Opioid
(administration & dosage)
- Chronic Pain
(diagnosis, drug therapy)
- Delayed-Action Preparations
(administration & dosage)
- Female
- Frail Elderly
- Humans
- Male
- Musculoskeletal Pain
(diagnosis, drug therapy)
- Pain Measurement
(drug effects, methods)
- Prospective Studies
- Severity of Illness Index
- Tapentadol
(administration & dosage)
|